JP2020503885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503885A5 JP2020503885A5 JP2019538535A JP2019538535A JP2020503885A5 JP 2020503885 A5 JP2020503885 A5 JP 2020503885A5 JP 2019538535 A JP2019538535 A JP 2019538535A JP 2019538535 A JP2019538535 A JP 2019538535A JP 2020503885 A5 JP2020503885 A5 JP 2020503885A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen receptor
- chimeric antigen
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 210000000822 natural killer cell Anatomy 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 230000004913 activation Effects 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 claims 2
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 claims 1
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 101100378956 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AMD2 gene Proteins 0.000 claims 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023004031A JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447898P | 2017-01-18 | 2017-01-18 | |
| US62/447,898 | 2017-01-18 | ||
| US201762467059P | 2017-03-03 | 2017-03-03 | |
| US62/467,059 | 2017-03-03 | ||
| US201762530193P | 2017-07-08 | 2017-07-08 | |
| US62/530,193 | 2017-07-08 | ||
| PCT/US2018/014122 WO2018136570A1 (en) | 2017-01-18 | 2018-01-17 | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023004031A Division JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503885A JP2020503885A (ja) | 2020-02-06 |
| JP2020503885A5 true JP2020503885A5 (https=) | 2021-03-04 |
| JP7280827B2 JP7280827B2 (ja) | 2023-05-24 |
Family
ID=61157332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538535A Active JP7280827B2 (ja) | 2017-01-18 | 2018-01-17 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
| JP2023004031A Active JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023004031A Active JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12187801B2 (https=) |
| EP (1) | EP3571229A1 (https=) |
| JP (2) | JP7280827B2 (https=) |
| KR (2) | KR20260006705A (https=) |
| CN (1) | CN110177808A (https=) |
| AU (1) | AU2018211081B2 (https=) |
| BR (1) | BR112019014615A2 (https=) |
| CA (1) | CA3049674A1 (https=) |
| IL (1) | IL267902B2 (https=) |
| MX (1) | MX2019008503A (https=) |
| SG (2) | SG10202107808SA (https=) |
| TW (1) | TWI860971B (https=) |
| WO (1) | WO2018136570A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2020047527A2 (en) * | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| CN116751298A (zh) | 2016-05-13 | 2023-09-15 | 生物蛋白有限公司 | 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途 |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
| EP3847191A4 (en) * | 2018-09-07 | 2022-06-08 | BioAtla, Inc. | CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS |
| CN111378039B (zh) * | 2018-12-29 | 2021-08-24 | 深圳大学 | 治疗恶性肿瘤的抗体及其应用 |
| CN111378040B (zh) * | 2018-12-29 | 2021-08-10 | 深圳大学 | 检测多种恶性肿瘤细胞的抗体及其应用 |
| WO2020143506A1 (zh) * | 2019-01-08 | 2020-07-16 | 深圳大学 | 检测多种恶性肿瘤细胞的抗体及其应用 |
| EP3715368A1 (en) | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
| JP2022529380A (ja) * | 2019-04-26 | 2022-06-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | キメラ抗原受容体構築物およびｃａｒ－ｔ細胞におけるそれらの使用 |
| CN110317277A (zh) * | 2019-07-10 | 2019-10-11 | 杭州普科亭生物医药有限公司 | 嵌合抗原受体及其应用 |
| CN112390894A (zh) * | 2019-08-12 | 2021-02-23 | 广东东阳光药业有限公司 | 嵌合抗原受体及其应用 |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| BR112022009611A2 (pt) * | 2019-11-18 | 2022-08-09 | Univ California | Anticorpos anti-ror-2 e métodos de uso |
| BR112022014568A2 (pt) * | 2020-01-23 | 2022-09-27 | Exuma Biotech Corp | Receptores de antígeno quiméricos contra her2 e métodos de uso dos mesmos |
| EP4114400A4 (en) * | 2020-03-05 | 2023-10-18 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| CN114075548B (zh) * | 2020-08-13 | 2023-11-21 | 广州医科大学附属第二医院 | 一种靶向axl的car-t细胞及其制备方法和应用 |
| AU2022212090A1 (en) | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN115125272B (zh) * | 2021-03-29 | 2024-04-19 | 复旦大学 | 一种car-t治疗载体及其构建方法和应用 |
| CN116102658B (zh) * | 2021-11-09 | 2025-04-29 | 四川大学华西医院 | 基于gas6构建的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| TW197439B (https=) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1993010076A1 (en) | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08500973A (ja) | 1992-05-21 | 1996-02-06 | ザ ペン ステイト リサーチ ファウンデーション | タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織 |
| US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
| US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
| US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
| CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
| FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
| FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
| FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
| FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| KR20060099543A (ko) | 1994-12-09 | 2006-09-19 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의 동정 |
| WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
| EP0961619A4 (en) | 1996-09-27 | 2001-09-26 | Bristol Myers Squibb Co | HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS |
| AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
| US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
| IL133585A0 (en) | 1997-06-20 | 2001-04-30 | Baker Norton Pharma | Soluble prodrugs of paclitaxel |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
| WO1999018113A1 (fr) | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| AU2008323206B2 (en) | 2007-11-12 | 2014-08-14 | U3 Pharma Gmbh | AXL antibodies |
| CA2706549A1 (en) | 2007-11-15 | 2009-05-22 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| US9464284B2 (en) | 2009-03-09 | 2016-10-11 | Bioatla, Llc | Mirac proteins |
| WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| CN103747803B (zh) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | 抗axl抗体及其用途 |
| US20140322234A1 (en) | 2012-01-03 | 2014-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis and Targeting of ROR2 in Cancer |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| US11111288B2 (en) * | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| US11673957B2 (en) * | 2015-03-10 | 2023-06-13 | Eureka Therapeutics, Inc. | Anti-ROR2 antibodies |
| EP3098237B1 (en) * | 2015-05-28 | 2018-08-01 | Universität Zu Köln | Anti-toso chimeric antigen receptor and its use |
| WO2017078839A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
| PL3443012T3 (pl) | 2016-04-15 | 2026-04-20 | Bioatla, Inc. | Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania |
| KR102873209B1 (ko) | 2016-08-31 | 2025-10-17 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 폴리펩티드 및 이를 제조하는 방법 |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
-
2018
- 2018-01-17 SG SG10202107808SA patent/SG10202107808SA/en unknown
- 2018-01-17 IL IL267902A patent/IL267902B2/en unknown
- 2018-01-17 WO PCT/US2018/014122 patent/WO2018136570A1/en not_active Ceased
- 2018-01-17 KR KR1020257042953A patent/KR20260006705A/ko active Pending
- 2018-01-17 BR BR112019014615-6A patent/BR112019014615A2/pt unknown
- 2018-01-17 US US16/478,360 patent/US12187801B2/en active Active
- 2018-01-17 CA CA3049674A patent/CA3049674A1/en active Pending
- 2018-01-17 SG SG11201906468TA patent/SG11201906468TA/en unknown
- 2018-01-17 JP JP2019538535A patent/JP7280827B2/ja active Active
- 2018-01-17 KR KR1020197024098A patent/KR102905343B1/ko active Active
- 2018-01-17 EP EP18703143.0A patent/EP3571229A1/en active Pending
- 2018-01-17 CN CN201880007323.XA patent/CN110177808A/zh active Pending
- 2018-01-17 MX MX2019008503A patent/MX2019008503A/es unknown
- 2018-01-17 AU AU2018211081A patent/AU2018211081B2/en active Active
- 2018-01-18 TW TW107101870A patent/TWI860971B/zh active
-
2023
- 2023-01-13 JP JP2023004031A patent/JP7700159B2/ja active Active
-
2024
- 2024-10-04 US US18/907,457 patent/US20250026840A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503885A5 (https=) | ||
| JP2021534770A5 (https=) | ||
| JP2019528077A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2020512820A5 (https=) | ||
| AU2020314509A1 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof | |
| JP2016533174A5 (https=) | ||
| MX2023005420A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2018172439A5 (https=) | ||
| JP2020517287A5 (https=) | ||
| JP2021525530A5 (https=) | ||
| JP2022513116A5 (https=) | ||
| JP2013529190A5 (https=) | ||
| JP2020517294A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2021512614A5 (https=) | ||
| JP2020532280A (ja) | 細胞により発現される生物学的活性を調節する結合分子 | |
| JP2017522891A5 (https=) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018528786A5 (https=) | ||
| JP2019515666A5 (https=) | ||
| JP2014518615A5 (https=) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JPWO2019232425A5 (https=) | ||
| JPWO2020077257A5 (https=) |